Dr. Richard Soll is presently Senior Advisor, Strategic Initiatives for the Research Service Division at WuXi AppTec and Head of the WuXi office in Cambridge, Massachusetts. His responsibilities also encompass initiatives in artificial intelligence at WuXi. He has held various leadership roles at WuXi as Senior Vice President including head of the medicinal chemistry unit known as the International Discovery Service Unit, business development, and corporate alliances.
Dr. Soll’s contributions led to the discovery of the HCV NS5A inhibitor elbasvir (a component of Zepatier®) in the Merck-WuXi partnership, the JAK2 inhibitor fedratinib at TargeGen which formed the basis of the $7B partnership between Celgene and Impact Biomedicines, and more than 10 other clinical stage drugs throughout his career. Dr. Soll is an advisory board member at the Blavatnik Center for Drug Discovery, Tel Aviv University.
Dr. Soll was CSO / VP of R&D at TargeGen and was VP of Chemistry at 3-Dimensional Pharmaceuticals. He started his career at Ayerst Research Labs (Wyeth and was trained as a synthetic chemist at Dartmouth and Harvard.
|9:00 AM - 9:40 AM||
Real Talk: An open discussion on the Urgency to Advance AI Applications in Industry to Bring Benefits to Patients Faster
AI is billed as a transformational technology for biopharma. As the use of AI, Machine Learning, and Advance Analytic tools increase it’s important to take stock and evaluate what are the successful applications and understand where biopharma as an industry is with applying AI tools. Join the conversation with: